Monocytes from male patients with ankylosing spondylitis display decreased osteoclastogenesis and decreased RANKL/OPG ratio.

Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
V F CaparboR M R Pereira

Abstract

The present study investigates the osteoclastogenic capacity of peripheral blood mononuclear cells (PBMCs) in male patients with ankylosing spondylitis (AS). We demonstrated that monocytes from these patients display a lower capacity to generate osteoclasts compared to cells from healthy controls, and osteoclastogenesis was negatively correlated with disease duration. Ankylosing spondylitis (AS) is a disease characterized by new bone growth that leads to syndesmophyte formation but AS patients frequently present with low bone mineral density/fractures. Osteoclastogenesis in AS patients is poorly studied and controversial. The aim of this study is to determine if the osteoclastogenic capacity of PBMCs is different in AS patients compared to controls and the relationship between osteoclastogenesis and clinical/laboratory parameters. PBMCs from 85 male AS patients and 59 controls were tested for CD16+ cells and induced to differentiate into osteoclasts over 3 weeks in vitro. Serum levels of RANKL, osteoprotegerin (OPG), C-terminal telopeptide of type I collagen (CTX), and amino-terminal pro-peptide of type I collagen (P1NP) were also evaluated. PBMCs from AS patients had fewer CD16+ cells and produced fewer osteoclasts compared to...Continue Reading

References

Mar 31, 2004·Annals of the Rheumatic Diseases·M C W CreemersP L C M van Riel
Jan 18, 2007·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Morten A KarsdalKim Henriksen
Feb 7, 2007·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Selda SarikayaOzgur Ortancil
May 1, 2007·Biochemical and Biophysical Research Communications·Akihiro NakaoKoji Okabe
May 29, 2007·Rheumatology·H Marzo-OrtegaD McGonagle
Jun 7, 2007·Current Opinion in Rheumatology·Eric Toussirot, Daniel Wendling
Nov 27, 2008·American Journal of Reproductive Immunology : AJRI·Christoph ScholzUdo Jeschke
May 15, 2009·Arthritis Research & Therapy·Rik J U LoriesKurt de Vlam
Jul 16, 2009·Inflammation & Allergy Drug Targets·Pooneh Salari, Mohammad Abdollahi
Oct 16, 2009·Journal of Dental Research·A KarakawaS Yamada
Nov 12, 2010·Annals of the Rheumatic Diseases·Pedro MachadoUNKNOWN Assessment of SpondyloArthritis international Society
Jun 8, 2011·Current Osteoporosis Reports·Shea Carter, Rik J Lories
Jun 21, 2011·Lancet·Maxime Dougados, Dominique Baeten
Mar 21, 2012·Immunologic Research·Kok Loon WongSiew Cheng Wong
Oct 23, 2012·Rheumatic Diseases Clinics of North America·Rik J U Lories, Georg Schett
Feb 4, 2014·The Journal of Rheumatology·Andrzej SurdackiTomasz K Grodzicki
Jun 17, 2014·The Journal of Rheumatology·Eva KlingbergHelena Forsblad-d'Elia
Aug 26, 2014·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·L P C SeguroR M R Pereira
Sep 13, 2014·Immunobiology·Huizhong Xiong, Eric G Pamer
Aug 5, 2015·Archives of Osteoporosis·Hrafnhildur L RunolfsdottirOlafur S Indridason
Oct 23, 2015·Journal of Cellular Physiology·Sara SprangersTeun J de Vries
Oct 29, 2015·RMD Open·Karine Briot, Christian Roux
May 11, 2016·Seminars in Arthritis and Rheumatism·Marina N MagreyMuhammad Asim Khan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis